<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39354108</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2399-3642</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Communications biology</Title><ISOAbbreviation>Commun Biol</ISOAbbreviation></Journal><ArticleTitle>Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages.</ArticleTitle><Pagination><StartPage>1239</StartPage><MedlinePgn>1239</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1239</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s42003-024-06951-7</ELocationID><Abstract><AbstractText>The continuous emergence of SARS-CoV-2 variants of concern has rendered many therapeutic monoclonal antibodies (mAbs) ineffective. To date, there are no clinically authorized therapeutic antibodies effective against the recently circulating Omicron sub-lineages BA.2.86 and JN.1. Here, we report the isolation of broad and potent neutralizing human mAbs (HuMabs) from a healthcare worker infected with SARS-CoV-2 early in the pandemic. These include a genetically unique HuMab, named K501SP6, which can neutralize different Omicron sub-lineages, including BQ.1, XBB.1, BA.2.86 and JN.1, by targeting a highly conserved epitope on the N terminal domain, as well as an RBD-specific HuMab (K501SP3) with high potency towards earlier circulating variants that was escaped by the more recent Omicron sub-lineages through spike F486 and E484 substitutions. Characterizing SARS-CoV-2 spike-specific HuMabs, including broadly reactive non-RBD-specific HuMabs, can give insight into the immune mechanisms involved in neutralization and immune evasion, which can be a valuable addition to already existing SARS-CoV-2 therapies.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Melanie R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Underwood</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Björnsson</LastName><ForeName>Kasper H</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0003-1339-8620</Identifier><AffiliationInfo><Affiliation>Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raghavan</LastName><ForeName>Sai Sundar Rajan</ForeName><Initials>SSR</Initials><Identifier Source="ORCID">0000-0002-2575-2685</Identifier><AffiliationInfo><Affiliation>Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassi</LastName><ForeName>Maria R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binderup</LastName><ForeName>Alekxander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7344-433X</Identifier><AffiliationInfo><Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Long V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Santseharay</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3699-1814</Identifier><AffiliationInfo><Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinholt</LastName><ForeName>Mette</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagil</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5594-0716</Identifier><AffiliationInfo><Affiliation>Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knudsen</LastName><ForeName>Anne S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idorn</LastName><ForeName>Manja</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6769-9165</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soegaard</LastName><ForeName>Max</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ExpreS2ion Biotechnologies, Hørsholm, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kaituo</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5922-7109</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0001-7153-3769</Identifier><AffiliationInfo><Affiliation>Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salanti</LastName><ForeName>Ali</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2207-5575</Identifier><AffiliationInfo><Affiliation>Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukh</LastName><ForeName>Jens</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7815-4806</Identifier><AffiliationInfo><Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barfod</LastName><ForeName>Lea</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6510-495X</Identifier><AffiliationInfo><Affiliation>Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. lbarfod@sund.ku.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NNF170C0026778</GrantID><Agency>Novo Nordisk Fonden (Novo Nordisk Foundation)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Commun Biol</MedlineTA><NlmUniqueID>101719179</NlmUniqueID><ISSNLinking>2399-3642</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057131" MajorTopicYN="N">Immune Evasion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39354108</ArticleId><ArticleId IdType="pmc">PMC11445456</ArticleId><ArticleId IdType="doi">10.1038/s42003-024-06951-7</ArticleId><ArticleId IdType="pii">10.1038/s42003-024-06951-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sohrabi, C. et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J. Surg.76, 71–76 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105032</ArticleId><ArticleId IdType="pubmed">32112977</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. WHO Coronavirus (COVID-19) Dashboard https://covid19.who.int/2022</Citation></Reference><Reference><Citation>WHO. Global excess deaths associated with COVID-19, January 2020 - December 2021. who.int; 2022 May 2022.</Citation></Reference><Reference><Citation>WHO. Tracking SARS-CoV-2 variants https://www.who.int/activities/tracking-SARS-CoV-2-variants2022.</Citation></Reference><Reference><Citation>Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med27, 622–625 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33654292</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr, T. N., Greaney, A. J., Dingens, A. S. &amp; Bloom, J. D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med2, 100255 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8020059</ArticleId><ArticleId IdType="pubmed">33842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giacomo, S., Mercatelli, D., Rakhimov, A. &amp; Giorgi, F. M. Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. J. Med Virol.93, 5638–5643 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242375</ArticleId><ArticleId IdType="pubmed">33951211</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupala, C. S., Ye, Y., Chen, H., Su, X. D. &amp; Liu, H. Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor. Biochem Biophys. Res Commun.590, 34–41 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8702632</ArticleId><ArticleId IdType="pubmed">34968782</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature602, 671–675 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, A. T. et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat. Commun.11, 4704 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499300</ArticleId><ArticleId IdType="pubmed">32943637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y. et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep.34, 108699 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7802522</ArticleId><ArticleId IdType="pubmed">33485405</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science367, 1260–1263 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell185, 457–66.e4 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8733787</ArticleId><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou, J. et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nat. Commun.13, 852 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828871</ArticleId><ArticleId IdType="pubmed">35140233</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature602, 654–656 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8866126</ArticleId><ArticleId IdType="pubmed">35016196</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, L. et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin Infect Dis. 75, e822–e826 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754807</ArticleId><ArticleId IdType="pubmed">34915551</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway, E. What Omicron’s BA.4 and BA.5 variants mean for the pandemic. Nature606, 848–849 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35750920</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas, D. et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. Nat. Commun.14, 824 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9926440</ArticleId><ArticleId IdType="pubmed">36788246</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell186, 279–86 e8 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare, S. et al. GISAID’s role in pandemic response. China CDC Wkly3, 1049–1051 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8668406</ArticleId><ArticleId IdType="pubmed">34934514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie, H. et al. Coronavirus Pandemic (COVID-19) OurWorldInData.org. Retrieved from: ‘https://ourworldindata.org/coronavirus'2020.</Citation></Reference><Reference><Citation>Yang, S. et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis.24, e70–e72 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38109919</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas, D. et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. bioRxiv. (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10938001</ArticleId><ArticleId IdType="pubmed">38480689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science369, 1010–1014 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299284</ArticleId><ArticleId IdType="pubmed">32540901</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol.21, 382–393 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054133</ArticleId><ArticleId IdType="pubmed">33875867</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, D., Sempowski, G. D., Saunders, K. O., Acharya, P. &amp; Haynes, B. F. SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. Annu Rev. Med.73, 1–16 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34428080</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasoba, D. et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect. Dis.22, 942–943 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9179126</ArticleId><ArticleId IdType="pubmed">35690075</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fdaauthorizes-new-monoclonal-antibodytreatment-covid-19-retains 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fdaauthorizes-new-monoclonal-antibodytreatment-covid-19-retains.</Citation></Reference><Reference><Citation>Dougan, M. et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv. 2022:2022.03.10.22272100.</Citation></Reference><Reference><Citation>Wang, Z. et al. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Immunity55, 998–1012.e8 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8986478</ArticleId><ArticleId IdType="pubmed">35447092</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker, M. R. et al. SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition. Viruses14, 1861 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9503696</ArticleId><ArticleId IdType="pubmed">36146667</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker, M. R. &amp; Barfod L. Production of PfEMP1-Specific Human Monoclonal Antibodies from Naturally Immune Individuals. In: Jensen A. T. R., Hviid L., editors. Malaria Immunology: Targeting the Surface of Infected Erythrocytes. New York, NY: Springer US; 2022. p. 407-421.</Citation><ArticleIdList><ArticleId IdType="pubmed">35881362</ArticleId></ArticleIdList></Reference><Reference><Citation>Hingankar, N. et al. A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. PLoS Pathog.18, e1010465 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9089897</ArticleId><ArticleId IdType="pubmed">35482816</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, L. et al. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Immunity56, 2442–55.e8 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10588992</ArticleId><ArticleId IdType="pubmed">37776849</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe29, 477–88.e4 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7839837</ArticleId><ArticleId IdType="pubmed">33535027</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature588, 682–687 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092461</ArticleId><ArticleId IdType="pubmed">33045718</ArticleId></ArticleIdList></Reference><Reference><Citation>Raybould, M. I. J., Kovaltsuk, A., Marks, C. &amp; Deane, C. M. CoV-AbDab: the coronavirus antibody database. Bioinformatics37, 734–735 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7558925</ArticleId><ArticleId IdType="pubmed">32805021</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, C. et al. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity54, 1276–1289.e6 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015430</ArticleId><ArticleId IdType="pubmed">33836142</ArticleId></ArticleIdList></Reference><Reference><Citation>Zost, S. J. et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat. Med.26, 1422–1427 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194108</ArticleId><ArticleId IdType="pubmed">32651581</ArticleId></ArticleIdList></Reference><Reference><Citation>Group AC–TfIwC-S. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir. Med.10, 972–984 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9270059</ArticleId><ArticleId IdType="pubmed">35817072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature614, 521–529 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, S. et al. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody. Sci. Adv.8, eadd2032 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9534492</ArticleId><ArticleId IdType="pubmed">36197988</ArticleId></ArticleIdList></Reference><Reference><Citation>De Cae, S. et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike. bioRxiv. 2023:2023.03.10.531533.</Citation></Reference><Reference><Citation>Lok, S. M. An NTD supersite of attack. Cell Host Microbe29, 744–746 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8114578</ArticleId><ArticleId IdType="pubmed">33984277</ArticleId></ArticleIdList></Reference><Reference><Citation>Elemento, O. &amp; Lefranc, M. P. IMGT/PhyloGene: an on-line tool for comparative analysis of immunoglobulin and T cell receptor genes. Dev. Comp. Immunol.27, 763–779 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12818634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature608, 593–602 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature608, 603–608 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>He, B. et al. Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq. Signal Transduct. Target Ther.6, 195 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8127497</ArticleId><ArticleId IdType="pubmed">34001847</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang, H. et al. Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients. Hum. Immunol.83, 119–129 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8566346</ArticleId><ArticleId IdType="pubmed">34785098</ArticleId></ArticleIdList></Reference><Reference><Citation>Jette, C. A. et al. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Rep.37, 110188 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8690285</ArticleId><ArticleId IdType="pubmed">34936878</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. FDA announces Evusheld is not currently authorized for emergency use in the U.S.: FDA; 2023 [updated 26/01/23. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us.</Citation></Reference><Reference><Citation>Hale, M. et al. IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2. J. Exp. Med.219, e20220849 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9365875</ArticleId><ArticleId IdType="pubmed">35938988</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosciences I. A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Intranasal Plus Intraoral IGM-6268 in Healthy Volunteers https://clinicaltrials.gov/2021. https://clinicaltrials.gov/ct2/show/NCT05160402.</Citation></Reference><Reference><Citation>Iversen, K. et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. Lancet Infect. Dis.20, 1401–1408 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7398038</ArticleId><ArticleId IdType="pubmed">32758438</ArticleId></ArticleIdList></Reference><Reference><Citation>Fougeroux, C. et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nat. Commun.12, 324 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804149</ArticleId><ArticleId IdType="pubmed">33436573</ArticleId></ArticleIdList></Reference><Reference><Citation>Barfod, L. et al. Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA. Mol. Microbiol.63, 335–347 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779471</ArticleId><ArticleId IdType="pubmed">17176260</ArticleId></ArticleIdList></Reference><Reference><Citation>Traggiai, E. et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med.10, 871–875 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095806</ArticleId><ArticleId IdType="pubmed">15247913</ArticleId></ArticleIdList></Reference><Reference><Citation>Alanine, D. G. W. et al. Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies. Cell178, 216–28 e21 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602525</ArticleId><ArticleId IdType="pubmed">31204103</ArticleId></ArticleIdList></Reference><Reference><Citation>Brochet, X., Lefranc, M. P. &amp; Giudicelli, V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res36, W503–W508 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2447746</ArticleId><ArticleId IdType="pubmed">18503082</ArticleId></ArticleIdList></Reference><Reference><Citation>Giudicelli, V., Brochet, X. &amp; Lefranc, M. P. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb. Protoc.2011, 695–715 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21632778</ArticleId></ArticleIdList></Reference><Reference><Citation>Solund, C. et al. Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA-mRNA or Vector-mRNA COVID-19 Vaccines. Vaccines (Basel)10, 75 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8780959</ArticleId><ArticleId IdType="pubmed">35062736</ArticleId></ArticleIdList></Reference><Reference><Citation>Underwood, A. P. et al. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19. EBioMedicine71, 103519 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8375401</ArticleId><ArticleId IdType="pubmed">34419923</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y. et al. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Sci. Adv.8, eadd7197 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9770952</ArticleId><ArticleId IdType="pubmed">36542720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez, S. et al. Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication. Antimicrob. Agents Chemother.65, e0009721 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406809</ArticleId><ArticleId IdType="pubmed">33903110</ArticleId></ArticleIdList></Reference><Reference><Citation>Underwood, A. P. et al. Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination. EBioMedicine89, 104475 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978324</ArticleId><ArticleId IdType="pubmed">36870117</ArticleId></ArticleIdList></Reference><Reference><Citation>Underwood, A. P. et al. Neutralizing antibody and CD8(+) T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2. Front Immunol.15, 1353353 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10987722</ArticleId><ArticleId IdType="pubmed">38571939</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahnoe, U. et al. Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication. Viruses14, 172 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8878408</ArticleId><ArticleId IdType="pubmed">35215765</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglewicz B., Hoaglin D. C. How to Detect and Handle Outliers: ASQC Quality Press; 1993.</Citation></Reference><Reference><Citation>Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science369, 1501–1505 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402631</ArticleId><ArticleId IdType="pubmed">32703906</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani, A., Rubinstein, J. L., Fleet, D. J. &amp; Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods14, 290–296 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bepler, T., Kelley, K., Noble, A. J. &amp; Berger, B. Topaz-Denoise: general deep denoising models for cryoEM and cryoET. Nat. Commun.11, 5208 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567117</ArticleId><ArticleId IdType="pubmed">33060581</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature596, 583–589 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng, E. C. et al. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci.32, e4792 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10588335</ArticleId><ArticleId IdType="pubmed">37774136</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard, T. D. et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci.27, 14–25 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734306</ArticleId><ArticleId IdType="pubmed">28710774</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley, P., Lohkamp, B., Scott, W. G. &amp; Cowtan, K. Features and development of Coot. Acta Crystallogr D. Biol. Crystallogr66, 486–501 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D. Struct. Biol.74, 531–544 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096492</ArticleId><ArticleId IdType="pubmed">29872004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, R. Y. et al. Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta. Elife5, e17219 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5115868</ArticleId><ArticleId IdType="pubmed">27669148</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhinandan, K. R. &amp; Martin, A. C. Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains. Mol. Immunol.45, 3832–3839 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18614234</ArticleId></ArticleIdList></Reference><Reference><Citation>Laskowski, R. A. &amp; Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model51, 2778–2786 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21919503</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol.7, 539 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261699</ArticleId><ArticleId IdType="pubmed">21988835</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooks, G. E., Hon, G., Chandonia, J. M. &amp; Brenner, S. E. WebLogo: a sequence logo generator. Genome Res.14, 1188–1190 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419797</ArticleId><ArticleId IdType="pubmed">15173120</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell, J. M., Chen, M., Baldwin, P. R. &amp; Ludtke, S. J. High resolution single particle refinement in EMAN2.1. Methods100, 25–34 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848122</ArticleId><ArticleId IdType="pubmed">26931650</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>